BERKELEY HEIGHTS, N.J., Feb. 25 /PRNewswire-FirstCall/ --
Genta Incorporated (Nasdaq: GNTA) today announced its participation at the
Raymond James & Associates' 24th Annual Institutional Investors Conference in
Orlando, Florida. Tara Spiess, Genta's Director of Investor Relations and
Corporate Communications, will provide an update on the Company's pipeline and
registration trials on Tuesday, March 4, 2003 at 8:05 a.m. EST.
A live audio webcast of the presentation can be accessed through Genta's
Investor Relations site at: http://www.genta.com/events.aspx. A replay will
be available for 30 days following the presentation.
About Genta
Genta Incorporated is a biopharmaceutical company with a diversified
product portfolio that is focused on anticancer therapy. The Company's
research platform is anchored by oligonucleotide chemistry, particularly
applications of antisense and decoy aptamer technology. Genasense(TM), the
Company's lead compound, is being developed in collaboration with Aventis and
is currently undergoing late-stage, Phase 3 clinical testing in several
clinical indications. Genta's pipeline also comprises a portfolio of small
molecules, including gallium-containing compounds and Androgenics compounds
for prostate cancer, as well as an anticancer series of DNA-based compounds
called "decoy aptamers." For more information about Genta, please visit our
website at: http://www.genta.com.
This press release and the webcast to follow contain forward-looking
statements with respect to business conducted by Genta Incorporated. By their
nature, forward-looking statements and forecasts involve risks and
uncertainties because they relate to events and depend on circumstances that
will occur in the future. There are a number of factors that could cause
actual results and developments to differ materially. For a discussion of
those risks and uncertainties, please see the Company's Annual Report/Form
10-K for 2001.
SOURCE Genta Incorporated
 back to top
Related links:
http://www.genta.com
http://www.genta.com/events.aspx
CONTACT:
Ms. Tara Spiess, Director, Investor Relations
and Corporate Communications of Genta Incorporated,
+1-908-286-3980
|
